The Caribbean Public Health Agency (CARPHA) is urging Ministries of Health and clinicians to only use the medicine, ivermectin, under the conditions of well-regulated clinical trials for COVID-19, or for approved indications.
“This is a result of the limited evidence available to assure a favorable benefit-risk balance when used in treating patients with COVID-19. This is also reflected by the recommendations of the global health authority, the (WHO),” CARPHA stated in a release.
In its “Therapeutics and COVID-19: Living Guideline”, March 31, 2021, the WHO Guideline Development Group explains “The effects of ivermectin on mortality, mechanical ventilation, hospital admission, duration of hospitalization and viral clearance remain uncertain because of very low certainty of evidence addressing each of these outcomes.”
The WHO in its press release on ivermectin also noted that the current evidence is of “very low certainty,” due to the small sizes and methodological limitations of available trial data.
